Iridex ( (IRIX) ) has released its Q2 earnings. Here is a breakdown of the information Iridex presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Iridex Corporation is a global leader in the development and marketing of innovative laser-based medical systems for treating glaucoma and retinal diseases, utilizing its proprietary MicroPulse technology to offer safe and effective solutions in the ophthalmology market.
In its second quarter of 2025, Iridex reported a revenue increase of 7% year-over-year, reaching $13.6 million, with notable growth in its retina product segment and a reduction in operating expenses by 28% compared to the previous year. The company also achieved its third consecutive quarter of positive non-GAAP adjusted EBITDA.
Key financial highlights include a stable performance in the Cyclo G6 product family, with revenue remaining flat at $3.3 million, and a significant improvement in net loss, which decreased to $1.0 million from $2.7 million in the same quarter last year. The company also reported a gross profit of $4.7 million, despite a decrease in gross margin due to increased manufacturing costs and a shift in product and geographic sales mix.
Looking ahead, Iridex remains committed to further reducing expenses and improving margins as it continues to focus on building a financially disciplined and self-sustaining business. The management is optimistic about maintaining revenue growth and achieving cash flow breakeven and positive adjusted EBITDA for the year 2025.